Skip to NavigationSkip to content

Business Services

LogiPharma/LogiMed Virtual Event Exclusively For Supply Chain & Logistics Innovators

DIA Global Annual Meeting 2021

CPhI Discover 2021

Optimization of design transfer from device development to final assembly

Benevolent AI and AstraZeneca expand collaboration on heart failure and systemic lupus discovery

Leading clinical stage AI drug discovery company, Benevolent AI, has expanded its AI-driven drug discovery collaboration with AstraZeneca. This means that the number of disease areas being explored through the partnership will be doubled.

The expansion builds on the partnership initiated in 2019, and adds systemic lupus erythematosus (SLE) and heart failure (HF) to research on identifying multiple novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

Abivax receive EMA scientific advice support for ulcerative colitis trial

Abivax have received scientific advice from the EMA supporting advancing ABX464 into Phase III clinical testing, for the treatment of ulcerative colitis, and for subsequent potential marketing authorisation submission and commercialisation.

Antifungal Cresemba (isavuconazole) approved for aspergillosis patients in China

Basilea Pharmaceutica, announced that its license partner, Pfizer, has received a Drug Approval License from the National Medical Products Administration (NMPA) in China for its antifungal Cresemba (isavucanazole), for the treatment of adult patients with invasive aspergillosis.

PCN-101 R-ketamine Programme receives FDA Investigational New Drug clearance

The FDA has given Investigational New Drug (IND) clearance to atai Life Sciences, to conduct a clinical DDI study of PCN-101 (R-ketamine). The DDI trial will complement an existing Phase IIa trial in treatment-resistant depression (TRD) recently initiated in Europe.

FDA grant Breakthrough Therapy Designation to telisotuzumab vedotin

AbbVie’s investigational telisotuzumab vedotin has been granted Breakthrough Therapy Designation by the FDA for the treatment of patients with advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.

Cyclenium Pharma and Vuja De Sciences collaborate on oncology drug discovery

Cyclenium Pharma, an emerging pharmaceutical company, have announced a collaboration with Vuja De Sciences, to screen and optimise lead candidates to advance treatments uniquely suited for preventing cancer metastatic recurrence.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches